CEO Executive AssistantWhy Launch Readiness Is the CEO’s Problem
A pharmaceutical product launch is among the most capital-intensive, time-compressed, and organizationally demanding events in any industry. A single approval can trigger a simultaneous mobilization of regulatory, manufacturing, commercial, medical affairs, market access, and communications functions, each operating under intense internal and external pressure.
The financial consequences of launch execution are enormous. Studies of pharmaceutical launch performance consistently show that peak sales trajectories are disproportionately influenced by the first twelve to eighteen months post-approval. Products that launch well sustain commercial momentum. Products that stumble in early launch frequently never recover their projected trajectory, regardless of subsequent corrective action.
Given these stakes, launch readiness is not a commercial operations problem or an R&D handoff problem. It is a CEO problem. The coordination required across functions, the capital decisions required ahead of approval, the external relationships that must be built before launch, and the culture of accountability required to execute reliably all require CEO-level leadership and visibility.
The Launch Readiness Timeline
Effective pharmaceutical launches do not begin at approval. They begin two to three years before anticipated approval, with a detailed readiness timeline that maps every critical activity across every function to specific milestones.
Three Years Before Launch: Strategic Foundation
At the three-year mark, the CEO’s operational priorities are strategic alignment and organizational design. This means finalizing the launch indication and label strategy, aligning the commercial model with the clinical profile of the product, and making key organizational decisions about whether the launch will be executed with existing teams, new hires, or external partners.
Strategic alignment at this stage also requires agreement on the target product profile: the specific clinical differentiation the organization will communicate to prescribers, payers, and patients. CEOs who allow ambiguity about differentiation to persist into launch execution will find that commercial, medical, and regulatory teams are operating from different mental models of the product, leading to inconsistent messaging and missed opportunities.
Two Years Before Launch: Infrastructure and Investment
The two-year window is when capital commitments for launch must be made, often before approval certainty exists. Manufacturing scale-up, distribution network development, field force hiring and training, and market access contracting all require lead times that extend well beyond the approval window.
CEOs who delay these investments to reduce pre-approval risk exposure often find themselves with approved products and insufficient infrastructure to execute the launch at the required scale. The financial model for launch investment should treat pre-approval spending as the cost of readiness, not as a speculative bet. For products with high probability of approval based on clinical data, the cost of under-investment typically exceeds the cost of the investment itself.
One Year Before Launch: Operational Readiness Validation
The final year before anticipated approval should be dedicated to readiness validation: systematic assessment of every function’s preparedness against the requirements of the launch plan. This is not a status report exercise. It is a genuine operational audit that surfaces gaps while there is still time to close them.
CEOs should receive a consolidated readiness report at 12 months, 6 months, and 3 months before anticipated approval. Each report should include a RAG (red, amber, green) status for each critical launch readiness domain, specific risk items requiring executive decision, and updated resource requirements. CEOs who receive summary reports without critical path visibility are often surprised by launch execution failures that were visible in the data months earlier.
Key Operational Domains for Launch Readiness
Market Access and Payer Strategy
Market access is consistently among the most challenging launch readiness domains, and the one most likely to underperform when under-resourced. Payer coverage decisions, particularly in the United States, increasingly precede or closely follow regulatory approval. Products that launch without secured access pathways face prescriber hesitation, patient affordability barriers, and competitive disadvantage against established therapies with favorable formulary placement.
CEOs should ensure market access strategy is developed in parallel with clinical development, not after approval. This means generating health economics data that supports formulary access, engaging with payer decision-makers during late-stage development, and designing patient support programs that address the cost barriers that would otherwise limit product uptake.
The alignment between health economics evidence and payer access strategy is addressed in pharma health economics, which provides a framework for ensuring these two functions operate in coordination.
Medical Affairs Launch Activation
Medical affairs plays a critical and often under-resourced role in pharmaceutical launches. The medical affairs team builds relationships with key opinion leaders in the target indication, generates scientific exchange and publication activity that precedes commercial promotion, and supports healthcare providers with the clinical education needed to use the product appropriately.
CEOs should treat medical affairs as a launch-critical function, not a supporting activity. This means ensuring medical affairs has dedicated launch resources, clear pre-commercial objectives, and accountability metrics tied to launch performance. The scientific narrative developed by medical affairs in the pre-launch period shapes how prescribers perceive the product at the moment commercial promotion begins. An under-resourced medical affairs function leaves that scientific positioning to competitors and clinical inertia.
Field Force Readiness
For products with broad prescriber targets, field force readiness is a major operational variable. Hiring, training, territory alignment, CRM configuration, and incentive design all require lead times that make the 12-month pre-launch window extremely tight if activities are not started earlier.
CEOs should review field force readiness metrics personally, including hiring completion rates against plan, training assessment scores, and territory coverage against the target prescriber list. Field force launches that are understaffed at approval day, or staffed with undertrained representatives, create first impressions with prescribers that are very difficult to reverse.
Supply Chain and Distribution
Supply chain readiness for a pharmaceutical launch involves manufacturing scale-up, quality release processes, distribution network activation, and inventory positioning. Each of these activities has its own timeline, regulatory requirements, and third-party dependencies.
CEOs should ensure the supply chain function is integrated into the launch readiness governance process and that supply risk is explicitly surfaced in executive readiness reviews. Supply shortfalls in early launch, which are far more common than they should be, signal that supply chain planning was not given adequate authority and resources during the pre-launch period.
Governance Structures for Launch Readiness
The Launch Steering Committee
A launch steering committee, chaired by the CEO or a direct report with cross-functional authority, is the primary governance mechanism for managing launch readiness. This committee meets monthly at the 24-month mark, moving to biweekly in the final six months, and weekly in the 60 days surrounding approval.
The committee’s function is not status reporting. It is decision-making: resolving cross-functional conflicts about resource allocation, making acceleration or risk-mitigation decisions, and escalating issues that require board or external stakeholder engagement. CEOs who attend steering committee meetings but treat them as informational receive very different launch performance than those who use the forum actively.
Cross-Functional Accountability Assignments
Each launch readiness domain should have a named executive owner accountable for delivering against the readiness plan. These ownership assignments should be explicit, documented, and tied to performance review. Organizations where launch readiness ownership is shared across committees or diffused across project teams consistently underperform those where individual executives are accountable for specific domains.
CEOs should review accountability assignments at the beginning of the launch readiness cycle and revisit them when organizational changes occur. Nothing erodes launch readiness faster than unresolved accountability ambiguity.
The Launch Period: First 90 Days
The first 90 days post-approval are the highest-intensity operational period in the launch cycle. This is when prescriber impressions form, payer access decisions crystallize, patient support programs are tested at scale, and supply chain assumptions are validated against real demand.
Real-Time Performance Monitoring
CEOs should establish a launch performance dashboard that provides weekly visibility into key launch indicators: prescription volume by week, prescriber activation rates, payer coverage wins and denials, patient support program enrollment and abandonment, and inventory levels relative to demand.
This dashboard should be reviewed by the CEO and leadership team weekly during the first 90 days. Early deviation from plan is much less costly to address than deviation identified at the 90-day review. Launches that appear to be tracking behind plan in weeks three through six can often be corrected with targeted resource reallocation or messaging adjustment. The same deviation identified at day 90 requires far more expensive corrective action.
Managing Expectations Internally and Externally
Launch performance pressure is intense, from investors, board members, and internal teams whose forecasting models were built on assumptions that may not survive contact with the market. CEOs should communicate launch performance context clearly and frequently, resisting the pressure to over-interpret early data in either direction.
The first four to six weeks of launch data are influenced by stocking patterns, early adopter prescribers, and competitive promotional response, none of which are reliable indicators of long-term trajectory. CEOs who allow early optimism to reduce launch investment intensity, or early pessimism to trigger premature strategic pivots, typically make the launch performance worse.
According to analysis from HBR, the most successful pharmaceutical launches share a common operational characteristic: a CEO who treats launch execution as a personal accountability and is visible in cross-functional governance throughout the readiness period. That executive engagement is not about micromanagement. It is about signaling organizational priority and ensuring that the capital and talent required for success are consistently available.
Building Launch Capability as Organizational Muscle
Each pharmaceutical launch is also an opportunity to build organizational capability for future launches. CEOs who conduct rigorous post-launch reviews, documenting what worked, what failed, and what the organization learned, build institutional knowledge that compounds across launch cycles.
The most commercially successful pharmaceutical organizations are those that have launched repeatedly and built launch excellence as a core operational competency. That competency is built deliberately, one launch at a time, by CEOs who treat each launch as both a performance event and a learning opportunity.
The pharma operations checklist provides a framework for auditing launch readiness processes against industry best practices and identifying the highest-priority gaps to close before the next approval event.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.